Multiple Sclerosis in 2025 – Key Developments to Date

In approximately 3 weeks, we will be celebrating World Multiple Sclerosis Day.  The theme in 2025 is ‘Navigating MS Together’, which perfectly aligns with everything that we stand for at MStranslate.  In line with that motto, we have authored this short article that explores a few of the big news stories that have happened in the first half of this year.

Tolebrutinib trial results published

We have known about the outcomes of this trial since ECTRIMS 2024, however, it was great to see the data finally made available.  The main ‘headline’ of these results is that the treatment was found to be effective in a cohort of people living with non-relapsing, secondary progressive multiple sclerosis.  The ‘non-relapsing’ part of this is important, as it means that there wasn’t a strong inflammatory aspect of their disease.  All our existing therapies target inflammation, which makes this result significant.  As it stands, tolebrutinib appears to be able to impact on the progressive or neurodegenerative part of MS – something that hasn’t been achieved before.  The US FDA is currently reviewing the data, so we will wait to see if and when this treatment is made available to people living with MS around the world.

CCMR Two trial finishes data collection

This trial, being conducted by the Cambridge Clinical MS Research Group, is one that we know our community are following with great interest.  The trial is testing the effectiveness of a combination of clemastine (an anti-histamine) and metformin (a diabetes drug) to promote myelin repair in people living with relapsing-remitting multiple sclerosis.  In a recent update, the researchers announced that the final participant in the trial had just completed their last clinic visit for data collection.  The study will now shift to months of data analysis, where the team will assess whether a significant difference was observed between people on medication compared to those that received placebo.  We expect the results of this trial to be presented in the second half of the year, potentially at ECTRIMS 2025 in Barcelona.

Those that are interested can stay up-to-date with all of the MS research projects being pursued in Cambridge by following them on Facebook, LinkedIn and/or YouTube.

Patient Community Day 2025

It is with great excitement that we can announce that MStranslate will once again be heavily involved in the Patient Community Day event, which will happen at the conclusion of the ECTRIMS 2025 Congress in Barcelona.  While we will definitely be releasing more information throughout the year in the lead-up, we can say that Brett will once again be hosting and moderating the event.  You can stay across everything that will be happening on Patient Community Day via the new website, which is available here.

If you have questions on any of these developments, please don’t hesitate to post them under this article or on any of our social media channels.

You can find us on Facebook, Twitter, YouTube, Instagram and LinkedIn.